Assessment of Minimal Residual Disease in Standard-Risk AML

Investigators seeking to identify genetic prognostic markers in a clinical trial to treat acute myeloid leukemia found that minimal residual disease, detected by the presence of mutation in NPM1, provided prognostic information independent of other risk factors. Although acute myeloid leukemia (AML)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2016-02, Vol.374 (5), p.422-433
Hauptverfasser:	Ivey, Adam, Hills, Robert K, Simpson, Michael A, Jovanovic, Jelena V, Gilkes, Amanda, Grech, Angela, Patel, Yashma, Bhudia, Neesa, Farah, Hassan, Mason, Joanne, Wall, Kerry, Akiki, Susanna, Griffiths, Michael, Solomon, Ellen, McCaughan, Frank, Linch, David C, Gale, Rosemary E, Vyas, Paresh, Freeman, Sylvie D, Russell, Nigel, Burnett, Alan K, Grimwade, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Base Sequence Chemotherapy Clinical trials DNA, Neoplasm - analysis Exome Gene Expression Profiling Genes Genetic markers Health risk assessment Humans Leukemia Leukemia, Myeloid, Acute - genetics Medical prognosis Minimal residual disease Molecular Sequence Data Multivariate analysis Mutation Myeloid leukemia Neoplasm, Residual - genetics Nuclear Proteins - genetics Nuclear Proteins - metabolism Nucleophosmin Patients Polymerase chain reaction Prognosis Quantitation Recurrence Remission Reverse Transcriptase Polymerase Chain Reaction Risk Factors Transcriptome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!